Experience
Israel Bio-Engineering Project v. Amgen Inc., et al.
Israel Bio-Engineering Project
Amgen Inc., Immunex Corp.
Successfully argued before the U.S. Court of Appeals for the Federal Circuit on behalf of Amgen and Immunex the appeal of a district court infringement action involving the important biologic drug Enbrel®. The Federal Circuit affirmed the district court’s grant of summary judgment regarding ownership of the patent in suit.
Israel Bio-Engineering Project v. Amgen Inc., Immunex Corp., 04-1153, 06-1218, Fed. Cir., Judge Klausner